Amag Pharmaceuticals Inc., of Waltham, reported results from its pharmacokinetic study designed to demonstrate comparable bioavailability of the subcutaneous auto-injector product and the current intramuscular (IM) injection form of Makena (hydroxyprogesterone caproate injection) in about 120 healthy postmenopausal women.